Agile Therapeutics Announces Proposed Offering of Common Stock
August 02, 2017 16:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that it intends to offer and sell shares of...
Agile Therapeutics Reports Second Quarter 2017 Financial Results
July 28, 2017 07:30 ET
|
Agile Therapeutics, Inc.
Cash Expected to Fund Operations into Q2 2018 FDA Assigns Prescription Drug User Fee Act (PDUFA) Goal Date of December 26, 2017 PRINCETON, N.J., July 28, 2017 (GLOBE NEWSWIRE) -- Agile...
Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
July 27, 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., July 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a forward-thinking women’s healthcare company, today announced that the U.S. Food and Drug Administration...
Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Contraceptive Patch, Twirla®
June 27, 2017 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., June 27, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced it has resubmitted to the U.S. Food and Drug Administration...
Agile Therapeutics Reports First Quarter 2017 Financial Results
May 08, 2017 16:11 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 08, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women's healthcare company today reported financial results for the three months ended March 31, 2017, and...
Agile Therapeutics Reports Additional Phase 3 SECURE Study Results Relating to Twirla® at ACOG 2017
May 06, 2017 14:05 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 06, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women’s healthcare company, today announced the presentation of additional results of its Phase 3 SECURE...
Agile Therapeutics to Present at the 2017 BIO CEO & Investor Conference
February 02, 2017 16:15 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...
Agile Therapeutics Announces Positive Top-line Phase 3 Results
January 03, 2017 16:11 ET
|
Agile Therapeutics, Inc.
Resubmission of Twirla® New Drug Application Expected to Address FDA’s Complete Response LetterCompany Plans to Resubmit NDA in First Half of...
Agile Therapeutics to Present at Biotech Showcase 2017
December 22, 2016 08:00 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) announced today that its Chief Executive Officer, Al Altomari will present at the Biotech Showcase 2017 on...
Agile Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference
December 22, 2016 07:30 ET
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Dec. 22, 2016 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX) a women’s health specialty pharmaceutical company, announced today that its Chief Executive Officer, Al...